Short-term H2 inhalation improves running performance and torso strength in healthy adults.
Dejan Javorac, Valdemar Stajer, Laszlo Ratgeber, Jozsef Betlehem, Sergej Ostojic · Biology of sport · 2019
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In 10 participants with a wash-out period of 7 days to prevent the residual effects of interventions across study periods, breathing 4% hydrogen for 20 min per day resulted in increased peak running velocity (by up to 4.2%) as compared to air inhalation (P = 0.05). These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 10 participants with a wash-out period of 7 days to prevent the residual effects of interventions across study periods. Breathing 4% hydrogen for 20 min per day resulted in increased peak running velocity (by up to 4.2%) as compared to air inhalation (P = 0.05).
What the Researchers Studied
The researchers studied 10 participants with a wash-out period of 7 days to prevent the residual effects of interventions across study periods. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
4% inhaled H₂ concentration; reported treatment duration: 7 days. Breathing 4% hydrogen for 20 min per day resulted in increased peak running velocity (by up to 4.2%) as compared to air inhalation (P = 0.05).
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human outcomes evaluated in this study and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled, crossover human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 10 participants with a wash-out period of 7 days to prevent the residual effects of interventions across study periods. The reported sample size was 10. The study used a randomized, double-blind, placebo-controlled, crossover human clinical trial. The reported hydrogen concentration was 4% inhaled H₂ concentration. The reported treatment duration was 7 days.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.